Unknown PHASE2 INTERVENTIONAL 3-arm NCT03487016

First-line Therapy in Metastatic PDAC (FOOTPATH)

A Multicenter Randomized Phase II Study to Determine the Optimal First-line Chemotherapy Regimen in Patients With Metastatic Pancreatic Cancer

Sponsor: Ludwig-Maximilians - University of Munich

Conditions Metastatic Pancreatic Cancer

Interventions 5-FU Gemcitabine Irinotecan Liposomal Injection Nab-paclitaxel Oxaliplatin

Updated 8 times since 2018 Last updated: Sep 7, 2022 Started: Feb 15, 2019 Primary completion: Jul 1, 2022 Completion: Jul 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03487016, this PHASE2 trial focuses on Metastatic Pancreatic Cancer and remains ongoing. Sponsored by Ludwig-Maximilians - University of Munich, it has been updated 8 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Oct 2024 — Present [monthly]

Unknown PHASE2

Status: Active Not Recruiting → Unknown
Sep 2024 — Oct 2024 [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2
Sep 2022 — Jul 2024 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Jan 2021 — Sep 2022 [monthly]

Recruiting PHASE2

▶ Show 3 earlier versions

Mar 2019 — Jan 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jun 2018 — Mar 2019 [monthly]

Not Yet Recruiting PHASE2
May 2018 — Jun 2018 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ludwig-Maximilians - University of Munich

Data source: Ludwig-Maximilians - University of Munich

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Munich, Germany